FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer.

[1]  F. Bellafiore,et al.  Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. , 2015, Journal of the National Cancer Institute.

[2]  T. Yoneda,et al.  The transcription factor Foxc1 is necessary for Ihh–Gli2-regulated endochondral ossification , 2015, Nature Communications.

[3]  Chunhong Yan,et al.  Determinants of Gli2 co‐activation of wildtype and naturally truncated androgen receptors , 2014, The Prostate.

[4]  T. Kume,et al.  Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation , 2014, Nature.

[5]  F. Abdul-Karim,et al.  FOXC1 Is Enriched in the Mammary Luminal Progenitor Population, but Is Not Necessary for Mouse Mammary Ductal Morphogenesis1 , 2013, Biology of reproduction.

[6]  S. Bagaria,et al.  Biology and Treatment of Basal-Like Breast Cancer , 2013 .

[7]  Hai-Feng Xu,et al.  High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients , 2013, Tumor Biology.

[8]  M. Zvelebil,et al.  Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers , 2013, Breast Cancer Research.

[9]  A. Gulino,et al.  Control of stem cells and cancer stem cells by Hedgehog signaling: pharmacologic clues from pathway dissection. , 2013, Biochemical pharmacology.

[10]  D. Fan,et al.  Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma , 2013, Hepatology.

[11]  Jeffrey T. Chang,et al.  FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. , 2013, Cancer research.

[12]  C. Rudin,et al.  Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. , 2013, Cancer cell.

[13]  A E Giuliano,et al.  FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling , 2012, Oncogene.

[14]  D. Robbins,et al.  The Hedgehog Signal Transduction Network , 2012, Science Signaling.

[15]  B. Karlan,et al.  A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission , 2012, Clinical Cancer Research.

[16]  H. Gómez,et al.  Behaviour of breast cancer molecular subtypes through tumour progression , 2012, Clinical and Translational Oncology.

[17]  S. Sizemore,et al.  The Forkhead Box Transcription Factor FOXC1 Promotes Breast Cancer Invasion by Inducing Matrix Metalloprotease 7 (MMP7) Expression* , 2012, The Journal of Biological Chemistry.

[18]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[19]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[20]  Kenneth K Wang,et al.  The crosstalk of mTOR/S6K1 and Hedgehog pathways. , 2012, Cancer cell.

[21]  S. Angers,et al.  Gli proteins in development and disease. , 2011, Annual review of cell and developmental biology.

[22]  André F. Vieira,et al.  Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.

[23]  P. Schofield,et al.  Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. , 2011, Cancer research.

[24]  F. D. de Sauvage,et al.  Clinical experience with Hedgehog pathway inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Beachy,et al.  Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector , 2010, Proceedings of the National Academy of Sciences.

[26]  A. Giuliano,et al.  FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. , 2010, Cancer research.

[27]  Angel Porgador,et al.  Cell type-specific DNA methylation patterns in the human breast , 2008, Proceedings of the National Academy of Sciences.

[28]  M. Ringnér,et al.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors , 2008, Breast Cancer Research.

[29]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[31]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[32]  C. D. Salcido,et al.  Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.

[33]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[34]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[35]  M. Lauth,et al.  Non-Canonical Activation of GLI Transcription Factors: Implications for Targeted Anti-Cancer Therapy , 2007, Cell cycle.

[36]  Allen Li,et al.  Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. , 2007, Cancer research.

[37]  T. Shimokawa,et al.  Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists , 2007, Proceedings of the National Academy of Sciences.

[38]  Jingwu Xie,et al.  Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells* , 2007, Journal of Biological Chemistry.

[39]  G. Dontu,et al.  Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. , 2006, Cancer research.

[40]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[41]  O. Lehmann,et al.  Axenfeld–Rieger malformation and distinctive facial features: Clues to a recognizable 6p25 microdeletion syndrome , 2005, American journal of medical genetics. Part A.

[42]  Masatoshi Nomura,et al.  Hedgehog Signaling Pathway is a New Therapeutic Target for Patients with Breast Cancer , 2004, Cancer Research.

[43]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Walter,et al.  FOXC1 Transcriptional Regulation Is Mediated by N- and C-terminal Activation Domains and Contains a Phosphorylated Transcriptional Inhibitory Domain* , 2002, The Journal of Biological Chemistry.

[45]  M. Scott,et al.  Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine , 2000, Nature.

[46]  B. Hogan,et al.  The Forkhead/Winged Helix Gene Mf1 Is Disrupted in the Pleiotropic Mouse Mutation congenital hydrocephalus , 1998, Cell.

[47]  M. Nakafuku,et al.  A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. , 1997, Development.

[48]  Massimo Cristofanilli,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013 .

[49]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .